These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35526750)

  • 1. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
    Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
    Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis.
    Garbez N; Mbatchi LC; Maseda E; Luque S; Grau S; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
    Ther Drug Monit; 2021 Dec; 43(6):747-755. PubMed ID: 33560097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid.
    Janssen PK; Foudraine NA; Burgers DM; Neef K; le Noble JL
    Ther Drug Monit; 2016 Dec; 38(6):699-705. PubMed ID: 27494946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
    Hanafin PO; Kwa A; Zavascki AP; Sandri AM; Scheetz MH; Kubin CJ; Shah J; Cherng BPZ; Yin MT; Wang J; Wang L; Calfee DP; Bolon M; Pogue JM; Purcell AW; Nation RL; Li J; Kaye KS; Rao GG
    Clin Microbiol Infect; 2023 Sep; 29(9):1174-1181. PubMed ID: 37217076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE-02).
    Kalaria SN; Armahizer M; McCarthy P; Badjatia N; Gobburu JV; Gopalakrishnan M
    Br J Clin Pharmacol; 2021 Nov; 87(11):4375-4385. PubMed ID: 33855736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Wang P; Liu D; Sun T; Zhang X; Yang J
    Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study.
    Tang T; Li Y; Xu P; Zhong Y; Yang M; Ma W; Xiang D; Zhang B; Zhou Y
    Crit Care; 2023 Apr; 27(1):164. PubMed ID: 37106370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients.
    Li Y; Deng Y; Zhu ZY; Liu YP; Xu P; Li X; Xie YL; Yao HC; Yang L; Zhang BK; Zhou YG
    Front Pharmacol; 2021; 12():727170. PubMed ID: 34512352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy.
    Sember AM; LoFaso ME; Lewis SJ
    J Crit Care; 2022 Jun; 69():154011. PubMed ID: 35202996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of a continuous infusion vancomycin dosing nomogram in critically ill patients undergoing continuous venovenous haemofiltration.
    Sin JH; Newman K; Elshaboury RH; Yeh DD; de Moya MA; Lin H
    J Antimicrob Chemother; 2018 Jan; 73(1):199-203. PubMed ID: 29040561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Brüggemann RJ; Lefrant JY; Roberts JA
    Clin Pharmacokinet; 2017 Sep; 56(9):1057-1068. PubMed ID: 28035589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
    Gao C; Tong J; Yu K; Sun Z; An R; Du Z
    Eur J Clin Pharmacol; 2016 Jul; 72(7):823-30. PubMed ID: 27023465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
    Sandri AM; Landersdorfer CB; Jacob J; Boniatti MM; Dalarosa MG; Falci DR; Behle TF; Bordinhão RC; Wang J; Forrest A; Nation RL; Li J; Zavascki AP
    Clin Infect Dis; 2013 Aug; 57(4):524-31. PubMed ID: 23697744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.